<!doctype html><html lang=cn><head><meta charset=utf-8><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1"><meta name=referrer content="no-referrer"><link rel=dns-prefetch href=https://i.geekbank.cf/><title>æŒ‡å—é€Ÿé€’ | 2019 ACOGå®è·µç®€æŠ¥ï¼šå¥³æ€§æ€§åŠŸèƒ½éšœç¢ï¼ˆNo.213ï¼‰ï¼ˆä¸Šï¼‰ | æå®¢å¿«è¨Š</title><meta property="og:title" content="æŒ‡å—é€Ÿé€’ | 2019 ACOGå®è·µç®€æŠ¥ï¼šå¥³æ€§æ€§åŠŸèƒ½éšœç¢ï¼ˆNo.213ï¼‰ï¼ˆä¸Šï¼‰ - æå®¢å¿«è¨Š"><meta property="og:type" content="article"><meta property="og:locale" content="cn"><meta property="og:image" content="https://p3.pstatp.com/large/pgc-image/23b99b468575493a94091b4c6c7516ec"><link rel=alternate hreflang=x-default href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/9a0f1cfd.html><link rel=alternate hreflang=zh-tw href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/9a0f1cfd.html><link rel=alternate hreflang=zh-cn href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%a6/9a0f1cfd.html><link rel=alternate hreflang=zh-hk href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/9a0f1cfd.html><link rel=alternate hreflang=zh-mo href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/9a0f1cfd.html><link rel=alternate hreflang=zh-my href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%a6/9a0f1cfd.html><link rel=alternate hreflang=zh-sg href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%a6/9a0f1cfd.html><link rel=canonical href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/9a0f1cfd.html><meta property="article:published_time" content="2020-11-14T20:58:37+08:00"><meta property="article:modified_time" content="2020-11-14T20:58:37+08:00"><meta name=Keywords content><meta name=description content="æŒ‡å—é€Ÿé€’ | 2019 ACOGå®è·µç®€æŠ¥ï¼šå¥³æ€§æ€§åŠŸèƒ½éšœç¢ï¼ˆNo.213ï¼‰ï¼ˆä¸Šï¼‰"><meta name=author content="æå®¢å¿«è¨Š"><meta property="og:url" content="/cn/%E7%A7%91%E5%AD%A6/9a0f1cfd.html"><link rel=apple-touch-icon sizes=180x180 href=../../apple-touch-icon.png><link rel=icon type=image/png sizes=32x32 href=../../favicon-32x32.png><link rel=icon type=image/png sizes=16x16 href=../../favicon-16x16.png><link rel=manifest href=../../site.webmanifest><link rel=mask-icon href=../../safari-pinned-tab.svg color=#5bbad5><meta name=msapplication-TileColor content="#ffc40d"><meta name=theme-color content="#ffffff"><link rel=stylesheet href=https://geekbank.cf/css/normalize.css><link rel=stylesheet href=https://geekbank.cf/css/style.css><script type=text/javascript src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js></script><script type=text/javascript src=https://geekbank.cf/js/jqthumb.min.js></script><script data-ad-client=ca-pub-3525055026201463 async src=https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js></script></head><body><header id=header class=clearfix><div class=container><div class=col-group><div class=site-name><h1><a id=logo href>ğŸ¤“ æå®¢å¿«è®¯ Geek Bank</a></h1><p class=description>ä¸ºä½ å¸¦æ¥æœ€å…¨çš„ç§‘æŠ€çŸ¥è¯† ğŸ§¡</p></div><div><nav id=nav-menu class=clearfix><a class=current href>çŒœä½ å–œæ­¡</a>
<a href=../../tw/categories/%E7%A7%91%E6%8A%80.html title=ç§‘æŠ€>ç§‘æŠ€</a>
<a href=../../tw/categories/%E9%81%8A%E6%88%B2.html title=éŠæˆ²>éŠæˆ²</a>
<a href=../../tw/categories/%E7%A7%91%E5%AD%B8.html title=ç§‘å­¸>ç§‘å­¸</a></nav></div></div></div></header><div id=body><div class=container><div class=col-group><div class=col-8 id=main><div class=res-cons><article class=post><header><h1 class=post-title>æŒ‡å—é€Ÿé€’ | 2019 ACOGå®è·µç®€æŠ¥ï¼šå¥³æ€§æ€§åŠŸèƒ½éšœç¢ï¼ˆNo.213ï¼‰ï¼ˆä¸Šï¼‰</h1></header><date class="post-meta meta-date">2020-11-14</date><div class=post-meta><span>|</span>
<span class=meta-category><a href=cn/categories/%E7%A7%91%E5%AD%A6.html>ç§‘å­¦</a></span></div><div class=post-content><div><p>è¯‘è€…ï¼šè°­æ™“ä¼Ÿ çƒŸå°æ¯“ç’œé¡¶åŒ»é™¢</p><p>å®¡æ ¡ï¼šå¾æ™– å±±ä¸œå¤§å­¦ç¬¬äºŒåŒ»é™¢</p><div class=pgc-img><img alt="æŒ‡å—é€Ÿé€’ | 2019 ACOGå®è·µç®€æŠ¥ï¼šå¥³æ€§æ€§åŠŸèƒ½éšœç¢ï¼ˆNo.213ï¼‰ï¼ˆä¸Šï¼‰" onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/23b99b468575493a94091b4c6c7516ec><p class=pgc-img-caption></p></div><p>å¥³æ€§æ€§åŠŸèƒ½éšœç¢</p><p>å¥³æ€§æ€§åŠŸèƒ½éšœç¢çš„æƒ…å†µæ˜¯å¤šæ–¹é¢çš„ï¼Œä¸»è¦æ˜¯å¯¹ä»¥ä¸‹ä¸€ç§æˆ–å¤šç§æ–¹é¢æ„Ÿåˆ°ç—›è‹¦ï¼šæ€§æ¬²æœ›ã€æ€§å†²åŠ¨ã€æ€§é«˜æ½®æˆ–æ€§äº¤ç–¼ç—›(1)ã€‚å°½ç®¡å¥³æ€§æ€§åŠŸèƒ½éšœç¢çš„é—®é¢˜ç›¸å¯¹æ¯”è¾ƒæ™®éï¼Œä½†æ˜¯å¥³æ€§ä¸å¤ªå¯èƒ½ä¸ä»–ä»¬çš„å«ç”Ÿä¿å¥æä¾›è€…ä¸»åŠ¨è®¨è®ºè¿™ä¸ªé—®é¢˜,é™¤éè¢«åˆ»æ„é—®åˆ°(2)ï¼Œè®¸å¤šå«ç”Ÿä¿å¥æä¾›è€…å› ä¸ºç§ç§åŸå› ä¹Ÿä¸æ„¿æ„é—®è¿™ä¸ªé—®é¢˜ï¼Œæ¯”å¦‚å…¶å¯¹æ€§åŠŸèƒ½éšœç¢æ‚£è€…çš„è¯Šæ–­ä¸ç®¡ç†ç¼ºä¹è¶³å¤Ÿçš„çŸ¥è¯†å’ŒåŸ¹è®­ï¼Œå¤„ç†é—®é¢˜çš„ä¸´åºŠæ—¶é—´ä¸å……è¶³ ï¼Œä½ä¼°äº†æ€§åŠŸèƒ½éšœç¢çš„æ™®éæ€§ã€‚æœ¬æ–‡çš„ç›®çš„æ˜¯å¯¹å¥³æ€§æ€§åŠŸèƒ½éšœç¢è¿›è¡Œç»¼è¿°ï¼Œæ¦‚è¿°æœ€æ–°çš„è¯Šæ–­æ ‡å‡†ï¼Œå¹¶æ ¹æ®ç°æœ‰çš„æœ‰æ•ˆè¯æ®è®¨è®ºç›®å‰æ¨èçš„ç®¡ç†ç­–ç•¥ã€‚</p><p>èƒŒæ™¯</p><p>å¤§çº¦æœ‰43%çš„ç¾å›½å¦‡å¥³æ›¾æŠ¥å‘Šè‡ªå·±åœ¨æ€§æ–¹é¢å­˜åœ¨é—®é¢˜ï¼Œæœ‰12%çš„äººå› æ€§åŠŸèƒ½éšœç¢å¯¼è‡´çš„ä¸ªäººç—›è‹¦è€Œæ„Ÿåˆ°å¾ˆçƒ¦æ¼ (3)ã€‚å¥³æ€§æ€§åŠŸèƒ½éšœç¢çš„å‘ç—…ç‡ä»ä¸­å¹´é˜¶æ®µå¼€å§‹å¢åŠ ï¼Œåœ¨18è‡³44å²å¹´é¾„æ®µçš„å¥³æ€§å½“ä¸­å¤§çº¦æœ‰10%å­˜åœ¨æ€§å›°æ‰°ï¼Œ 45è‡³64å²å¹´é¾„æ®µçš„å¥³æ€§å­˜åœ¨æ€§å›°æ‰°é—®é¢˜çš„æ¯”ä¾‹è¾¾åˆ°15% çš„å³°å€¼ï¼Œç„¶ååœ¨è€å¹´é˜¶æ®µåˆä¸‹é™ï¼Œåœ¨65è‡³85å²å¹´é¾„æ®µçš„è€å¹´å¥³æ€§ä¸­ï¼Œæ€§åŠŸèƒ½éšœç¢çš„å‘ç—…ç‡ä¸‹é™åˆ°9%å·¦å³(3)ã€‚è¡¨æ¡†1åˆ—å‡ºäº†ä¸€äº›æ›´å¸¸è§çš„æ€§åŠŸèƒ½éšœç¢çš„ç—…å› å’Œå±é™©å› ç´ ã€‚</p><p>æ­£å¸¸æ€§ååº”</p><p>å¯¹äºå¥³æ€§æ­£å¸¸æ€§ååº”çš„æœ€åˆç ”ç©¶å€¾å‘äºçº¿æ€§æ¨¡å‹(4-6)ã€‚è€Œæ›´ç°ä»£å¥³æ€§æ€§ååº”æ¨¡å‹æ˜¯éçº¿æ€§çš„ï¼ŒåŒ…æ‹¬å¥³æ€§æ€§ååº”åŸå§‹å››ä¸ªé˜¶æ®µä»¥åŠå…¶ä»–é˜¶æ®µçš„å„ç§åºåˆ— (å›¾1)(7)ã€‚ä»Šå¤©ï¼Œæˆ‘ä»¬æŠŠä¸­æ¢ç¥ç»å†…åˆ†æ³Œç³»ç»Ÿé€šè¿‡è°ƒæ•´æ€§å…´å¥‹å’Œæ€§æŠ‘åˆ¶å› ç´ ä¹‹é—´å¹³è¡¡æ¥è°ƒèŠ‚å¥³æ€§æ€§ååº”çš„è¿‡ç¨‹æè¿°ä¸ºåŠ¨æ€çš„è¿‡ç¨‹ (8)ã€‚</p><p>é›Œæ¿€ç´ åœ¨å¥³æ€§æ€§ç”Ÿç†(åŒ…æ‹¬ç»´æŒç”Ÿæ®–å™¨å®˜ç»„ç»‡çš„æ•æ„Ÿæ€§ã€å¼¹æ€§ã€åˆ†æ³Œç‰©ã€pHå€¼å’Œå¾®ç”Ÿç‰©èŒç¾¤)ã€æ’å°¿èŠ‚å¾‹ã€ç›†åº•è‚Œå¼ åŠ›å’Œå…³èŠ‚æ´»åŠ¨æ–¹é¢èµ·ç€å…³é”®ä½œç”¨(8,12)ã€‚å¤–å‘¨è¡€é›Œæ¿€ç´ éšç€å¥³æ€§çš„è¡°è€è‡ªç„¶å‡å°‘ï¼Œä¹Ÿä¼šå› æ‰‹æœ¯æˆ–è¯ç‰©æ‰€è‡´é›Œæ¿€ç´ å‡å°‘å¯¼è‡´æ›´å¹´æœŸçš„åˆ°æ¥ï¼Œé›Œæ¿€ç´ çš„è¿™äº›å˜åŒ–ä¼šå¯¹å¥³æ€§æ€§åŠŸèƒ½äº§ç”Ÿå¤šç§å¤šæ ·çš„å½±å“(7,12)ã€‚</p><p>å¥³æ€§çš„é›„æ¿€ç´ æ°´å¹³åœ¨20å¤šå²æ—¶è¾¾åˆ°é¡¶å³°ï¼Œåœ¨è‚²é¾„æœŸæ—©æœŸ(ç›´åˆ°30å¤šå²)æ€¥å‰§ä¸‹é™ï¼Œåœ¨60å²å·¦å³è¶‹äºç¨³å®šï¼Œè‡ª60å²ä»¥åä¸å†è¿›ä¸€æ­¥çš„ä¸‹é™(13-15)ã€‚ç¾é…®åœ¨è°ƒèŠ‚å¥³æ€§æ€§æ¬²å’Œæ€§åŠŸèƒ½æ–¹é¢çš„ä½œç”¨å°šä¸æ¸…æ¥šã€‚è™½ç„¶æœ‰è¯æ®è¡¨æ˜çŸ­æœŸåº”ç”¨ç»çš®å¸æ”¶ç¾é…®è¯ç‰©å¯¹æ€§æ¬²ä½ä¸‹çš„ç»ç»åå¦‡å¥³æœ‰ç›Šï¼Œä½†æ˜¯å¹¶æ²¡æœ‰ç‰¹å®šçš„é›„æ¿€ç´ æˆ–é›„æ¿€ç´ å‰ä½“è¡€æ¸…æ°´å¹³æˆ–ä¸‹é™å€¼å¯ä½œä¸ºå¥³æ€§æ€§åŠŸèƒ½å‡é€€çš„è¯Šæ–­æ ‡å‡†(16-18)ã€‚</p><p>æ€§åŠŸèƒ½éšœç¢çš„ç±»å‹</p><p>ç¾å›½ç²¾ç¥ç—…å­¦åä¼šçš„ã€Šç²¾ç¥éšœç¢è¯Šæ–­ä¸ç»Ÿè®¡å­¦æ‰‹å†Œ(ç¬¬äº”ç‰ˆ)ã€‹(DSM-5)ç¡®å®šäº†å››ç§ç‰¹å®šç±»å‹çš„å¥³æ€§æ€§åŠŸèƒ½éšœç¢(1)(è¡¨æ¡†1)ã€‚æ­¤å¤–ï¼ŒDSM-5è¿˜å°†æ€§åŠŸèƒ½éšœç¢åˆ†ä¸ºâ€œå…¶ä»–ç‰¹å®šæ€§åŠŸèƒ½éšœç¢â€å’Œâ€œéç‰¹å®šæ€§åŠŸèƒ½éšœç¢â€ã€‚</p><div class=pgc-img><img alt="æŒ‡å—é€Ÿé€’ | 2019 ACOGå®è·µç®€æŠ¥ï¼šå¥³æ€§æ€§åŠŸèƒ½éšœç¢ï¼ˆNo.213ï¼‰ï¼ˆä¸Šï¼‰" onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/10f840477fa04985904559448ac6f8c8><p class=pgc-img-caption></p></div><p>å¥³æ€§æ€§æ¬²å’Œè§‰é†’éšœç¢</p><p>å¥³æ€§æ€§æ¬²è§‰é†’éšœç¢æ˜¯ä¸€ç§æ–°çš„åˆ†ç±»ï¼Œå®ƒå–ä»£äº†DSM-IVæœ¯è¯­ä¸­çš„æ€§æ¬²å‡é€€å’Œå¥³æ€§æ€§è§‰é†’éšœç¢ã€‚(åœ¨æœ¬æ–‡ä»¶ä¸­ï¼Œæ€§æ¬²å‡é€€ä»…ç”¨äºæè¿°ä½¿ç”¨DSM-IV-TRæ ‡å‡†è€ƒé‡çš„ä¸€ç§æ¡ä»¶æˆ–ç»“æœçš„ç ”ç©¶ã€‚)æ€§æ¬²å’Œæ€§å”¤èµ·çš„æ³¢åŠ¨å¯èƒ½ä¼šä¼´éšå¥³æ€§ä¸€ç”Ÿï¼Œè¿™äº›æ³¢åŠ¨ç”±ä¸€äº›ä¸ªäººçš„ æˆ–æ€§ä¼´ä¾£å› ç´ å¼•èµ·ï¼Œä½†æ˜¯å¸¸å¸¸ä¼šè¢«å¿½ç•¥ã€‚è¿™äº›å› ç´ åŒ…æ‹¬ç¡çœ æ¨¡å¼çš„æ”¹å˜æˆ–é•¿æœŸç¡çœ è´¨é‡ä¸‹é™ï¼Œå‹åŠ›ï¼Œèº«ä½“å¤–è²Œã€èº«ææˆ–ä½“é‡çš„å˜åŒ–ï¼Œå¦Šå¨ ï¼Œå“ºä¹³ï¼Œä¹…åä¸åŠ¨çš„ç”Ÿæ´»æ–¹å¼ï¼Œé…—é…’æˆ–å…¶ä»–è¯ç‰©æ»¥ç”¨ï¼Œäººé™…å…³ç³»å› ç´ ç­‰(19-26)ã€‚è®¸å¤šå¥³æ€§è¯´å¥¹ä»¬ç¼ºä¹æ€§æ¬²æœ›æˆ–æ€§å†²åŠ¨ï¼Œæ„å‘³ç€å¥¹ä»¬å·²ç»å¤±å»äº†å¯¹æ€§çš„ç”Ÿç†æ¸´æœ›ã€‚å¥¹ä»¬æè¿°äº†æ€§çš„é—®é¢˜ï¼Œä½†æ˜¯ä»–ä»¬è€ƒè™‘çš„æ˜¯å¦‚ä½•é¿å…æ€§è¡Œä¸ºï¼Œæˆ–è€…æ˜¯å¦‚ä½•é€šè¿‡æ€§è¡Œä¸ºæ¥ç»´æŒä¸€æ®µæ„Ÿæƒ…æˆ–è€…æ˜¯é€šè¿‡æ€§æ¥æ»¡è¶³å…¶ä¼´ä¾£çš„éœ€æ±‚ (27)ã€‚å¥³æ€§è¿˜æè¿°äº†ä¸€ç§ç—›è‹¦ï¼Œå°±æ˜¯å¥¹ä»¬è™½ç„¶å¯¹æ€§æ²¡æœ‰å…´è¶£ï¼Œä½†æ˜¯å½“å…¶æ€§ä¼´ä¾£å¼€å§‹æœ‰æ€§æ´»åŠ¨æ—¶ï¼Œå¥¹ä»¬ä¹Ÿèƒ½è¢«å”¤é†’ (27)ã€‚</p><p>è™½ç„¶å¥³æ€§çš„æ€§å…´è¶£å’Œæ€§å”¤èµ·éšœç¢é—®é¢˜å¯ä»¥åœ¨æ²¡æœ‰è¯Šæ–­å‡ºçš„å¹¶å‘ç—…çš„æƒ…å†µä¸‹å‘ç”Ÿï¼Œä½†æ–°çš„å¹¶å‘ç—…å¯èƒ½æ˜¯æœªè¢«è¯Šæ–­æˆ–äºšä¸´åºŠæ¡ä»¶ä¸‹çš„ä¸€ä¸ªæŒ‡æ ‡ï¼Œç”šè‡³åœ¨å¹´è½»å¥³æ€§ç¾¤ä½“ä¸­ä¹Ÿæ˜¯å¦‚æ­¤(28)ã€‚è¯ç‰©æ²»ç–—ï¼Œç‰¹åˆ«æ˜¯é€‰æ‹©æ€§è¡€æ¸…ç´ å†æ‘„å–æŠ‘åˆ¶å‰‚(SSRIs)ï¼Œé€šå¸¸ä¸æ€§å”¤èµ·ç›¸å…³(æ¡†1)(29)ã€‚</p><div class=pgc-img><img alt="æŒ‡å—é€Ÿé€’ | 2019 ACOGå®è·µç®€æŠ¥ï¼šå¥³æ€§æ€§åŠŸèƒ½éšœç¢ï¼ˆNo.213ï¼‰ï¼ˆä¸Šï¼‰" onerror=errorimg.call(this); src=https://p9.pstatp.com/large/pgc-image/fb929134d5854a8ab0f5c52b072ea4cd><p class=pgc-img-caption></p></div><p>æœŸå¾…æ¬²æœ›ã€ç”Ÿç†å”¤é†’ã€ä¸»è§‚å”¤é†’ã€æ€§å”¤é†’åŠæ¬²æœ›å“åº”ã€å›æŠ¥ï¼ˆèº«ä½“æˆ–å¿ƒç†æ»¡è¶³ï¼‰ã€æ€§åŠ¨æœºã€ä¸»è§‚è‡ªæ„¿ã€æ€§åˆºæ¿€åŠç¯å¢ƒã€å¤§è„‘å¤„ç†ä¿¡æ¯ã€‚</p><p>æ¡†1æ‰€ç¤ºã€‚å¥³æ€§çš„æ€§ååº”ã€‚å¾ªç¯çš„æ€§ååº”å‘¨æœŸå‘ˆç°å‡ºé‡å çš„å˜é˜¶å¼é˜¶æ®µã€‚æ€§åŠ¨æœºæœ‰å¾ˆå¤šï¼Œæ€§æ¬²å¯èƒ½åœ¨ä¸€å¼€å§‹å°±å­˜åœ¨ï¼Œä¹Ÿå¯èƒ½ä¸å­˜åœ¨ï¼Œä½†åœ¨å¤§è„‘å°†æ€§ä¿¡å·å¤„ç†ä¸ºæ€§å”¤é†’(ä¸æ€§æ¬²åˆå¹¶)ä¹‹åä¾¿äº§ç”Ÿäº†æ€§åŠ¨æœºã€‚åè€…è¿›ä¸€æ­¥å¢å¼ºæ€§å†²åŠ¨ï¼Œå…è®¸æ¥å—é€æ¸å¼ºçƒˆçš„æ€§åˆºæ¿€ã€‚</p><p>(Basson R. Sexuality and sexual disorders. Clin Update Womens Health Care 2014;XIII(2);1â€“108. Available at:https://www.clinicalupdates.org/viewissue.cfm?</p><p>issue5cuwhc-v13n2. Retrieved February 22,2019.)</p><div class=pgc-img><img alt="æŒ‡å—é€Ÿé€’ | 2019 ACOGå®è·µç®€æŠ¥ï¼šå¥³æ€§æ€§åŠŸèƒ½éšœç¢ï¼ˆNo.213ï¼‰ï¼ˆä¸Šï¼‰" onerror=errorimg.call(this); src=https://p9.pstatp.com/large/pgc-image/b98f10b52a304a97b754c35b170a38f8><p class=pgc-img-caption></p></div><p>*å½“å¥³æ€§å­˜åœ¨æ€§åŠŸèƒ½éšœç¢æ—¶ï¼Œåªè¦æ’é™¤æ— æ€§çš„ç²¾ç¥ç–¾ç—…ã€æ€§ä¼´ä¾£ç—›è‹¦å…³ç³»ï¼ˆæ¯”å¦‚æ€§ä¼´ä¾£æš´åŠ›ï¼‰ã€åŒ–å­¦ç‰©è´¨ã€è¯ç‰©åŠå…¶ä»–åŒ»å­¦æ²»ç–—å¼•èµ·çš„æ€§åŠŸèƒ½éšœç¢å°±å¯è¯Šæ–­ä¸ºæ€§åŠŸèƒ½éšœç¢ç–¾ç—…ã€‚</p><p>æ€§åŠŸèƒ½éšœç¢æ— æ³•ç”¨ä¸€ç§ç‹¬ç«‹çš„æ€§åŠŸèƒ½éšœç¢ç–¾ç—…æ¥è¯ é‡Šã€‚æœ‰è¯æ®è¡¨æ˜ï¼ŒéåŒ–å­¦ç‰©è´¨/è¯ç‰©å¼•èµ·çš„æ€§åŠŸèƒ½éšœç¢ï¼Œåº”åŒ…æ‹¬æœ‰ç‹¬ç«‹çš„æ€§åŠŸèƒ½éšœç¢ç—…å²ï¼Œåœ¨åº”ç”¨åŒ–å­¦ç‰©è´¨æˆ–è¯ç‰©æ²»ç–—å‰å°±å­˜åœ¨ç—‡çŠ¶ï¼Œåœ¨æ€¥æ€§æˆ’æ–­æˆ–ä¸¥é‡ä¸­æ¯’ç»ˆæ­¢åç—‡çŠ¶è‡³å°‘æŒç»­ä¸€ä¸ªæœˆã€‚</p><p>Data from American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): APA;2013.</p><p>å¥³æ€§æ€§é«˜æ½®éšœç¢</p><p>å¥³æ€§æ€§é«˜æ½®éšœç¢çš„å®šä¹‰ä¸ºæ˜æ˜¾çš„æ€§é«˜æ½®æ—¶é—´å»¶è¿Ÿã€æ€§é«˜æ½®ç¨€å‘ã€æ— æ€§é«˜æ½®æˆ–æ˜æ˜¾çš„é«˜æ½®å¿«æ„Ÿå¼ºåº¦é™ä½(1)ã€‚åŸå‘æ€§æ€§é«˜æ½®éšœç¢çš„å¥³æ€§é€šå¸¸æœ‰æ­£å¸¸çš„æ€§æ¬²æ°´å¹³(27)ã€‚å¤§å¤šæ•°æ€§é«˜æ½®éšœç¢æ‚£è€…æ˜¯è·å¾—æ€§çš„ï¼Œä¸æ–°å¼€å§‹çš„åŒ»å­¦æ²»ç–—ã€è§£å‰–å­¦å¼‚å¸¸ã€ä¼´ä¾£å…³ç³»ä¸å’Œè°ã€ä¸ªäººè¡Œä¸ºæ”¹å˜ã€ä»¥åŠå¿ƒç†çŠ¶å†µç›¸å…³ (è¡¨æ¡†1)ï¼Œé€šå¸¸è¡¨ç°ä¸ºæ€§æ¬²åŠæ€§è§‰é†’éšœç¢ã€ç”Ÿæ®–å™¨ç›†è…”ç—›åŠé˜´é“æ’å…¥éšœç¢ç—‡çŠ¶å¹¶å­˜ (1)ã€‚åœ¨ä¸ªåˆ«ç½•è§æ¡ˆä¾‹å½“ä¸­ï¼Œè·å¾—æ€§é«˜æ½®éšœç¢å¯èƒ½æ˜¯ç”±æ½œåœ¨ç¥ç»ç³»ç»Ÿç–¾ç—…ã€ç”Ÿæ®–å™¨æˆ–ç›†åº•æ‰‹æœ¯ç›¸å…³æŸä¼¤ã€æ”¾ç–—æˆ–è¯ç‰©æ²»ç–—å¼•èµ· (1 7)ã€‚å°½ç®¡ç ”ç©¶èµ„æ–™éå¸¸æœ‰é™,ä½†æ˜¯æ¥å—è¿‡ç”Ÿæ®–å™¨å®˜åˆ‡é™¤æ‰‹æœ¯çš„å¥³æ€§å¯èƒ½æœ‰ç»ˆç”Ÿæ€§é«˜æ½®éšœç¢æˆ–è·å¾—æ€§æ€§é«˜æ½®éšœç¢ï¼Œä¸”å¥¹ä»¬æ‚£æ€§åŠŸèƒ½éšœç¢çš„é£é™©æ›´é«˜(30)ã€‚</p><p>ç”Ÿæ®–å™¨ç›†è…”ç—›å’Œé˜´é“æ’å…¥éšœç¢</p><p>é˜´é“ç—‰æŒ›å’Œæ€§äº¤å›°éš¾ç°åœ¨å·²å¹¶å…¥ç”Ÿæ®–å™¨-ç›†è…”ç–¼ç—›å’Œé˜´é“æ’å…¥éšœç¢ã€‚è¿™ç§éšœç¢å¯èƒ½æ˜¯ç»ˆç”Ÿçš„ï¼Œä¹Ÿå¯èƒ½æ˜¯åå¤©è·å¾—æ€§çš„ã€‚ç”Ÿæ®–å™¨-ç›†è…”ç–¼ç—›å’Œé˜´é“æ’å…¥éšœç¢åŒ…æ‹¬ä»¥ä¸‹ä¸€ç§æˆ–å¤šç§ç—‡çŠ¶ï¼šé˜´é“è‚Œè‚‰ç´§ç¼©ï¼Œæ¥å—æ’å…¥çš„èƒ½åŠ›é™ä½æˆ–æ ¹æœ¬æ— æ³•æ¥å—é˜´èŒæ’å…¥ï¼›æ€§ä¼´ä¾£å°è¯•æ’å…¥é˜´é“æ—¶å¥³æ€§ä¼šæ„Ÿåˆ°ç´§å¼ ã€ç–¼ç—›æˆ–ç¼çƒ§æ„Ÿï¼›æ€§äº¤çš„æ¬²æœ›å‡å°‘æˆ–æ²¡æœ‰æ€§äº¤æ¬²æœ›ï¼›é€ƒé¿æ€§è¡Œä¸ºï¼›å¯¹ç–¼ç—›çš„å¼ºçƒˆææƒ§ä¸å®³æ€• (1)ã€‚ç”Ÿæ®–å™¨-ç›†è…”ç–¼ç—›å’Œé˜´é“æ’å…¥éšœç¢çš„ç—‡çŠ¶å¸¸å¸¸åŒæ—¶å‡ºç°ï¼Œå¤šæ˜¯ç”±é‡å çš„åŒ»å­¦ã€ç¯å¢ƒå’Œå¿ƒç†ç¤¾ä¼šåŸå› ä¸€èµ·å¯¼è‡´çš„ï¼Œè§£é™¤è¿™äº›ç—…å› åï¼Œç–¼ç—›æˆ–é˜´é“æ’å…¥éšœç¢ç—‡çŠ¶ä¾¿å¯å¾—åˆ°ç¼“è§£ (31,32)ã€‚éœ€è¦æ³¨æ„çš„æ˜¯ï¼Œå³ä¾¿æ‚£è€…çš„æ€§è¡Œä¸ºä¸åŒ…æ‹¬æ€§äº¤ï¼Œåªè¦å¥¹ä»¬å­˜åœ¨æ€§åŠŸèƒ½ç›¸å…³ç–¼ç—›ï¼Œé‚£ä¹ˆå¥¹ä»¬ä»ç„¶å¯èƒ½æ‚£æœ‰è¿™ç§ç–¾ç—…ã€‚</p><p>åŒ–å­¦ç‰©è´¨æˆ–è¯ç‰©å› ç´ æ‰€è‡´æ€§åŠŸèƒ½éšœç¢</p><p>åŒ–å­¦ç‰©è´¨æˆ–è¯ç‰©å¼•èµ·çš„æ€§åŠŸèƒ½éšœç¢æ˜¯ä¸´åºŠä¸Šä¸€ç§é‡è¦çš„æ€§åŠŸèƒ½éšœç¢ï¼Œå¤šå‘ç”Ÿäºæœç”¨æŸç§è¯ç‰©æ—¶ï¼Œæˆ–æœè¯åä¸ä¹…ï¼Œæˆ–åœæœæŸç§è¯ç‰©æ—¶ã€‚è¿™äº›åŒ–å­¦ç‰©è´¨æˆ–è¯ç‰©å¾ˆå®¹æ˜“è¢«è®¤ä¸ºæœ‰å¼•èµ·æ€§åŠŸèƒ½éšœç¢çš„ä½œç”¨ (1)ã€‚ä¸å…¶ä»–ç±»å‹çš„å¥³æ€§æ€§åŠŸèƒ½éšœç¢ç›¸æ¯”,è¿™ç§æ€§åŠŸèƒ½éšœç¢çš„è¯Šæ–­è¦æ±‚ç—…äººæœ‰ç›¸å…³çš„ç—›è‹¦ç»å†ã€‚æŠ—èƒ†ç¢±èƒ½è¯ç‰©ã€æ¿€ç´ è¯ç‰©ã€å¿ƒè¡€ç®¡ç—…è¯ç‰©å’Œç²¾ç¥ç—…è¯ç‰©å¯èƒ½ä¸å¥³æ€§æ€§åŠŸèƒ½éšœç¢æœ‰å…³(24)ã€‚é…’ç²¾ã€å¤§éº»å’Œéº»é†‰å‰‚ä¹Ÿå¯èƒ½å¯¼è‡´å¥³æ€§æ€§åŠŸèƒ½éšœç¢ã€‚</p><p>å…¶ä»–ç‰¹å®šæˆ–éç‰¹å®šæ€§åŠŸèƒ½éšœç¢</p><p>ç—…äººè¡¨ç°å‡ºæ€§åŠŸèƒ½éšœç¢çš„ç—›è‹¦ç—‡çŠ¶ï¼Œä½†æ˜¯åˆä¸ç¬¦åˆå·²ç»å®šä¹‰çš„æ€§åŠŸèƒ½éšœç¢çš„åˆ†ç±»æ ‡å‡†ï¼Œè¿™ç§æ€§åŠŸèƒ½éšœç¢å¯ä»¥è¯Šæ–­ä¸ºå…¶ä»–ç‰¹å®šæˆ–éç‰¹å®šæ€§åŠŸèƒ½éšœç¢ (1)ã€‚å…¶ä»–ç‰¹å®šæ€§åŠŸèƒ½éšœç¢å’Œå…¶ä»–éç‰¹å®šæ€§åŠŸèƒ½éšœç¢ä¹‹é—´ä¸»è¦åŒºåˆ«æ˜¯ä¸´åºŠåŒ»ç”Ÿç¡®å®šå¼•èµ·æ‚£è€…æ‰€æè¿°ç—‡çŠ¶çš„ç—…å› ä¸ç¬¦åˆå…¶ä»–æ€§åŠŸèƒ½éšœç¢åˆ†ç±»æ ‡å‡†ã€‚</p><p>å¦Šå¨ ç›¸å…³æ€§åŠŸèƒ½éšœç¢</p><p>ä»»ä½•ç±»å‹çš„å­•æœŸæ€§åŠŸèƒ½éšœç¢éƒ½æ˜¯äº§åæ€§åŠŸèƒ½éšœç¢çš„ä¸€ä¸ªå…³é”®é£é™©å› ç´ ã€‚å‰–å®«äº§ã€å™¨æ¢°åŠ©äº§ã€ä¼šé˜´åˆ‡å¼€æœ¯å’Œä¼šé˜´æ’•è£‚å¼•èµ·çš„åˆ›ä¼¤ä¹Ÿä¼šå¢åŠ å‘ç”Ÿäº§åç”Ÿæ®–å™¨-ç›†è…”ç—›å’Œé˜´é“æ’å…¥éšœç¢ç–¾ç—…çš„é£é™©ï¼Œå¹¶ä¸æ€§æ¬²å’Œæ€§è§‰é†’åŠŸèƒ½éšœç¢å­˜åœ¨ç›¸å…³æ€§ (33-36)ã€‚æ¯ä¹³å–‚å…»è¿˜ä¼šå¯¼è‡´é˜´é“å¹²ç‡¥ï¼Œä»è€Œå‡ºç°ç”Ÿæ®–å™¨-ç›†è…”ç–¼ç—›/é˜´é“æ’å…¥éšœç¢çš„ç—‡çŠ¶ã€‚å¥³æ€§äº§åé¢ä¸´è®¸å¤šé—®é¢˜ï¼Œæ¯”å¦‚é•¿æœŸç¡çœ ç´Šä¹±ï¼Œæ¯äº²è§’è‰²æ”¹å˜ï¼Œå®¶åº­å…³ç³»é—®é¢˜ï¼Œæ–°ç”Ÿå„¿å¥åº·é—®é¢˜ï¼Œäº²å­å…³ç³»ç¤¾ä¼šå¿ƒç†è°ƒæ•´(å¯¹å¥³æ€§å’Œå¥¹çš„ä¼´ä¾£)ï¼Œäº§åèº«ä½“æ”¹å˜ã€‚è¿™äº›å¥³æ€§äº§åé—®é¢˜ä¸äº§ç§‘åˆ†å¨©ç›¸å…³å› ç´ ç›¸æ¯”ï¼Œäº§ç§‘å› ç´ ä¼¼ä¹æ˜¯äº§åå¥³æ€§æ€§åŠŸèƒ½éšœç¢æ›´é‡è¦çš„é©±åŠ¨å› ç´  (35)ã€‚äº§åæŠ‘éƒç—‡é™¤äº†ä¸æ€§æ¬²å‡é€€å’Œæ€§ç”Ÿæ´»é¢‘ç‡é™ä½æœ‰å…³å¤–(37)ï¼Œè¿˜å¯èƒ½æœ‰æ½œåœ¨çš„ä¸¥é‡å¥åº·é£é™©ï¼Œéœ€è¦æ—©å‘ç°å¹¶åŠæ—¶å¹²é¢„ (38)ã€‚å®¶åº­æš´åŠ›åœ¨æ€€å­•æœŸé—´å¯èƒ½å‡çº§ï¼Œå¯¹å¦‡å¥³åŠå…¶æ–°ç”Ÿå„¿çš„æ•´ä½“å¥åº·å’Œå¹¸ç¦æ„æˆä¸¥é‡å¨èƒï¼Œå¹¶ä¸äº§åæ€§åŠŸèƒ½éšœç¢æœ‰å…³(39)ã€‚äº§åå¥³æ€§æ€§åŠŸèƒ½éšœç¢çš„è¯„ä¼°å’Œç®¡ç†ç±»ä¼¼äºéäº§åå¥³æ€§æ€§åŠŸèƒ½éšœç¢çš„è¯„ä¼°ã€ç®¡ç†å’Œæ²»ç–—ï¼Œåªæ˜¯è¿›è¡Œäº†ä¸€äº›ä¿®æ”¹ï¼Œä»¥é¿å…åº”ç”¨å“ºä¹³æœŸç¦ç”¨çš„åŒ»å­¦æ²»ç–—ã€‚</p><p>æ›´å¹´æœŸç›¸å…³æ€§åŠŸèƒ½éšœç¢</p><p>2014å¹´ï¼Œæ ¹æ®ç¾å›½å¥³æ€§æ€§å¥åº·ä¸åŒ—ç¾æ›´å¹´æœŸåä¼šçš„ç ”ç©¶ï¼Œå›½é™…å­¦ä¼šæå‡ºç»ç»åæ³Œå°¿ç”Ÿæ®–ç³»ç»Ÿç»¼åˆå¾çš„æœ¯è¯­ï¼Œè¿™ä¸€æœ¯è¯­ä¸ä½†æç»˜äº†é˜´é“èç¼©ï¼ŒåŒæ—¶è¿˜åŒ…å«äº†å…¨éƒ¨ç”Ÿæ®–ç³»ç»Ÿæ”¹å˜ã€æ€§åŠŸèƒ½éšœç¢ç—‡çŠ¶åŠæ³Œå°¿ç³»ç»Ÿç—‡çŠ¶ï¼Œè¿™äº›ç—‡çŠ¶å‡ä¸æ›´å¹´æœŸå‘ç”Ÿçš„å¤–å‘¨è¡€é›Œæ¿€ç´ åŠå…¶ä»–ç±»å›ºé†‡æ¿€ç´ æ°´å¹³ä¸‹é™æœ‰å…³ (12)ã€‚å…¸å‹ç—‡çŠ¶åŒ…æ‹¬ä»¤äººçƒ¦æ¼çš„é˜´é“å¹²æ¶©ã€ç¼çƒ§å’Œåˆºæ¿€æ„Ÿï¼›æ€§äº¤æ—¶é˜´é“æ¶¦æ»‘æ€§é™ä½åŠæ€§äº¤ç–¼ç—›ï¼›å°¿æ€¥ã€æ’å°¿å›°éš¾å’Œå¤å‘æ€§å°¿è·¯æ„ŸæŸ“ (12)ã€‚æ®ä¼°è®¡ï¼Œé«˜è¾¾50%çš„æ›´å¹´æœŸå¦‡å¥³å—åˆ°æ›´å¹´æœŸæ³Œå°¿ç”Ÿæ®–ç³»ç»Ÿç»¼åˆå¾ç›¸å…³ç—‡çŠ¶çš„å½±å“(40,41)ï¼Œåœ¨è‚²é¾„æœŸï¼Œæ›´å¹´æœŸæ³Œå°¿ç”Ÿæ®–ç³»ç»Ÿç»¼åˆå¾ä¹Ÿå¯èƒ½å‘ç”Ÿï¼Œæ¯”å¦‚ä½é›Œæ¿€ç´ çŠ¶æ€(å¦‚äº§å)æˆ–ä½¿ç”¨èŠ³é¦™åŒ–é…¶æŠ‘åˆ¶å‰‚ç­‰æŠ—æ¿€ç´ è¯ç‰©æœŸé—´(42,43)ã€‚</p><p>ä¸´åºŠæ€è€ƒä¸å»ºè®®</p><p><strong>å¦‚ä½•è¿›è¡Œå¥³æ€§æ€§åŠŸèƒ½éšœç¢ç­›æŸ¥ï¼Ÿ</strong></p><p>å¦‡äº§ç§‘åŒ»ç”Ÿåº”åœ¨æ—¥å¸¸å¯¹ç—…äººè¿›è¡Œè¯Šç–—ä¸éšè®¿æœŸé—´å°±å¼€å§‹å¯¹æ€§åŠŸèƒ½è¿›è¡Œä¸´åºŠè®¨è®ºï¼Œä»¥ç¡®å®šå¯èƒ½éœ€è¦è¿›ä¸€æ­¥æ¢è®¨çš„é—®é¢˜ï¼Œå¹¶å¸®åŠ©æ¶ˆé™¤æ‚£è€…å¯¹è®¨è®ºæ€§åŠŸèƒ½é—®é¢˜çš„åè§(44-46)ã€‚åœ¨æ‚£è€…å…¥é™¢æ—¶è®©å…¶å¡«å†™ç®€çŸ­çš„æ€§åŠŸèƒ½è‡ªæŸ¥è¡¨ï¼Œä¾‹å¦‚ä½¿ç”¨æ‚£è€…æŠ¥å‘Šçš„ç»“æœæµ‹é‡ä¿¡æ¯ç³»ç»Ÿç ”ç©¶æ¡†æ¶ï¼ˆ47ï¼‰å¼€å‘çš„ç»è¿‡éªŒè¯çš„å•é¡¹é€‰æ‹©é¢˜ï¼Œå¯èƒ½æœ‰åŠ©äºä¿ƒè¿›å¯¹æ€§åŠŸèƒ½çš„ä¸´åºŠè®¨è®ºã€‚åœ¨æ—¥å¸¸å«ç”Ÿä¿å¥è®¿è°ˆä¸­ä»‹ç»æ€§åŠŸèƒ½çš„å¦ä¸€ç§æ–¹æ³•æ˜¯ä½¿ç”¨ä¸€ç§å®½æ³›çš„é™ˆè¿°æ¨¡å¼ï¼Œç›®çš„æ˜¯ä½¿é—®é¢˜æ­£å¸¸åŒ–ï¼Œç„¶åæ˜¯ä¸€ä¸ªå°é—­å¼é—®é¢˜å’Œä¸€ä¸ªå¼€æ”¾å¼é—®é¢˜(48)ã€‚ä¾‹å¦‚ï¼Œâ€œè®¸å¤šå¥³æ€§éƒ½ç»å†è¿‡å¯¹æ€§çš„æ‹…å¿§ï¼Œä½ åœ¨æ€§æ–¹é¢æœ‰ä»€ä¹ˆé—®é¢˜å—(æ˜¯/å¦)? ä½ åœ¨æ‹…å¿ƒä»€ä¹ˆ?â€æå‡ºè¿™ä¸ªè¯é¢˜çš„å¦ä¸€ç§æ–¹å¼æ˜¯åœ¨æ—¥å¸¸çš„èšä¼šä¸­æå‡ºå®½æ³›çš„ã€å¼€æ”¾å¼çš„é—®é¢˜ã€‚å¦‚æœå‘ç°äº†æ€§æ–¹é¢çš„é—®é¢˜ï¼Œå»ºè®®è¿›è¡Œåç»­è¯„ä¼°ã€‚</p><p><strong>å¯¹äºå¯èƒ½å­˜åœ¨æ€§åŠŸèƒ½éšœç¢çš„å¦‡å¥³ï¼Œæˆ‘ä»¬åº”è¯¥å¦‚ä½•åˆæ­¥å¤„ç†ï¼Ÿ</strong></p><p>å¯¹å¥³æ€§æ€§åŠŸèƒ½éšœç¢æ‚£è€…çš„åˆæ­¥è¯„ä¼°å¯èƒ½éœ€è¦è¾ƒé•¿æ—¶é—´çš„éšè®¿ï¼Œå¹¶åº”åŒ…æ‹¬ç»¼åˆç—…å²é‡‡é›†(45ã€46ã€49ã€51)å’Œä½“æ ¼æ£€æŸ¥ï¼Œä»¥è¯„ä¼°å¯èƒ½çš„å¦‡ç§‘ç—…å› ã€‚åœ¨æœ€åˆè¯„ä¼°å¥³æ€§æ€§åŠŸèƒ½éšœç¢æ—¶ï¼Œé€šå¸¸ä¸éœ€è¦å®éªŒå®¤æ£€æµ‹ï¼Œé™¤éæ€€ç–‘æœ‰æœªè¯Šæ–­çš„åŒ»å­¦ç—…å› ã€‚</p><p>å…¨é¢çš„ç—…å²é‡‡é›†</p><p>è¯¦ç»†çš„æ€§ç”Ÿæ´»å²åº”åŒ…æ‹¬ç—…äººçš„æ€§ç”Ÿæ´»å’Œæ€§åˆ«è®¤åŒé—®é¢˜ï¼›æ€§åŠŸèƒ½éšœç¢ç—‡çŠ¶çš„æ€§è´¨ã€æŒç»­æ—¶é—´å’Œå‘ç—…æ—¶é—´ï¼›ä¸ªäººå¯¹ç—‡çŠ¶æœ‰æ€æ ·çš„è‹¦æ¼ï¼›è‡ªæˆ‘ä¿å¥æƒ…å†µã€è‡ªæˆ‘ç”¨è¯æƒ…å†µæˆ–å…¶ä»–æ¥å—è¿‡å“ªäº›å‡è½»ç—‡çŠ¶çš„æ²»ç–—ï¼›æ€§ä¼´ä¾£å› ç´ ï¼ŒåŒ…æ‹¬ç›®å‰çš„æ€§ä¼´ä¾£æ•°é‡ä»¥åŠä»–ä»¬çš„æ€§ç”Ÿæ´»æƒ…å†µã€èº«ä½“å¥åº·é—®é¢˜å’Œæ€§åŠŸèƒ½é—®é¢˜ï¼›ä¸æ€§ä¼´ä¾£çš„å…³ç³»æ˜¯å¦èæ´½ï¼ŒåŒ…æ‹¬ç—…äººçš„æ€§é—®é¢˜ï¼›æ—¢å¾€å’Œç°åœ¨æ‰€é­å—çš„è™å¾…æˆ–æš´åŠ›(44,52)ï¼›å¯èƒ½å½±å“ç”Ÿæ®–å™¨-ç›†è…”éƒ¨ä½çš„ä¸ªäººä½“åŠ›åŠ³åŠ¨ã€æŸä¼¤(å¦‚è·¨éª‘ä¼¤æˆ–å°¾éª¨ä¼¤)å’Œç”Ÿæ´»ä¹ æƒ¯(å¦‚ä¸ªäººå«ç”Ÿå’Œä¹…å)ï¼›ç¡çœ è´¨é‡ï¼›ä¸ªäººèº«ä½“å˜åŒ–æˆ–å½¢è±¡é—®é¢˜(å¦‚ä¹³æˆ¿åˆ‡é™¤æœ¯ã€é€ ç˜˜æœ¯åæˆ–å¦Šå¨ )(49,51)ã€‚åŒæ ·ï¼Œç³Ÿç³•çš„ä¼´ä¾£å…³ç³»å’Œä¼´ä¾£æ€§åŠŸèƒ½éšœç¢ä¹Ÿåº”è¯¥å¾—åˆ°è®¤çŸ¥å’Œè§£å†³ã€‚ç”±äºä¸€ç§æ€§åŠŸèƒ½éšœç¢å¯èƒ½å¼•å‘å¦ä¸€ç§æ€§é—®é¢˜ (ä¾‹å¦‚ï¼Œç–¼ç—›å¯èƒ½å¯¼è‡´æ€§æ¬²ä¸§å¤±)ï¼Œåº”è¯„ä¼°ç°ç—‡æƒ…å†µä»¥åŠç—‡çŠ¶æœªæ¥çš„å‘å±•æƒ…å†µã€‚äº†è§£å¤„æ–¹è¯å’Œéå¤„æ–¹è¯ç‰©å’ŒåŒ–å­¦ç‰©è´¨çš„ä½¿ç”¨æƒ…å†µã€‚åœ¨ç§‘ç ”é¢†åŸŸï¼Œæˆ‘ä»¬å·²ç»æœ‰äº†å„ç§æœ‰æ•ˆçš„è‡ªæˆ‘æŠ¥å‘Šé—®å·æ¥è¯„ä¼°æœ‰æ€§åŠŸèƒ½éšœç¢ç—‡çŠ¶å¥³æ€§çš„æ€§åŠŸèƒ½ï¼Œè¿™äº›é—®å·ä¹Ÿå¯èƒ½ç”¨æ¥å¸®åŠ©è¿›è¡Œä¸´åºŠè®¿è°ˆå’Œæ€§ç”Ÿæ´»å²é‡‡é›† (53)ã€‚ä¾‹å¦‚å¥³æ€§æ€§åŠŸèƒ½æŒ‡æ•°(54)å’Œå¥³æ€§æ€§å›°æ‰°é‡è¡¨(55)ã€‚</p><p>ä½“æ ¼æ£€æŸ¥</p><p>ä¸€èˆ¬æ¥è¯´ï¼Œå¦‡ç§‘æ£€æŸ¥çš„é‡ç‚¹æ˜¯åœ¨ç—…å²é‡‡é›†æ—¶å·²ç»ç¡®å®šçš„é‡ç‚¹éƒ¨ä½ï¼Œå¯ä»¥å¸®åŠ©æˆ‘ä»¬è¯„ä¼°å¯èƒ½å¯¼è‡´æˆ–ä¿ƒæˆæ€§åŠŸèƒ½éšœç¢çš„åŸå‘æ€§å¦‡ç§‘ç–¾ç—… (56)ã€‚æ­£åœ¨æ¥å—å¥³æ€§æ€§åŠŸèƒ½éšœç¢æ£€æŸ¥çš„å¦‡å¥³å¯èƒ½ä¼šå—ç›Šäºæœ‰æœºä¼šåœ¨é•œå­çš„å¸®åŠ©ä¸‹æŸ¥çœ‹å’Œå‚ä¸æ£€æŸ¥ã€‚å¯¹å…¶è¿›è¡Œç®€çŸ­çš„ç”Ÿæ®–å™¨å®˜æ•™è‚²,åŒ…æ‹¬è§‚çœ‹ç”Ÿæ®–å™¨å®˜æ’å›¾ï¼Œè¯†åˆ«é˜´è’‚ï¼Œé˜´å”‡ï¼Œå°¿é“ï¼Œé˜´é“å£ï¼Œé˜´é“å‰å…ã€‚å¯ä»¥å¸®åŠ©ç—…äººæ›´å¥½çš„å‘Šè¯‰åŒ»ç”Ÿç–¼ç—›çš„ä½ç½®ä»¥åŠå…¶ä»–æ€§åŠŸèƒ½éšœç¢ç—‡çŠ¶çš„æƒ…å†µã€‚ä¹Ÿå¯ä»¥å¸®åŠ©å«ç”Ÿä¿å¥æä¾›è€…æ›´å¥½çš„è·Ÿç—…äººæ²Ÿé€šä½“æ ¼æ£€æŸ¥ç»“æœå¹¶æå‡ºæ²»ç–—å»ºè®®ã€‚æœ‰ä¸€ç§æç»˜ç–¼ç—›ç—‡çŠ¶çš„æ–¹æ³•æ˜¯ä½¿ç”¨æ£‰ç­¾ç³»ç»Ÿåœ°è½»è§¦å‰åº­æ¥å®šä½ä¸é€‚åŒºåŸŸ(57)ï¼Œå°½ç®¡è¿™é¡¹æµ‹è¯•çš„ç‰¹å¼‚æ€§å—åˆ°äº†äººä»¬çš„è´¨ç–‘(58)ã€‚</p><p>è¯Šæ–­</p><p>æ€§åŠŸèƒ½éšœç¢ç—‡çŠ¶æŒç»­è‡³å°‘6ä¸ªæœˆ(é™¤å¤–åŒ–å­¦ç‰©è´¨/è¯ç‰©å¼•èµ·çš„æ€§åŠŸèƒ½éšœç¢)ï¼Œå¹¶ä¸”ç»™ç—…äººé€ æˆæ˜æ˜¾çš„ä¸ªäººç—›è‹¦ï¼Œè¯Šæ–­ä¸ºDSM-5å¥³æ€§æ€§åŠŸèƒ½éšœç¢(è¡¨1)ã€‚æ­¤å¤–ï¼Œè¯Šæ–­éœ€æ’é™¤éæ€§å¿ƒç†å¥åº·éšœç¢ã€åŒ»ç–—çŠ¶å†µã€ä¸¥é‡çš„äººé™…å…³ç³»å›°æ‰°æˆ–å…¶ä»–é‡å¤§çš„ç”Ÿæ´»å‹åŠ›ï¼Œä»¥åŠåŒ–å­¦ç‰©è´¨æˆ–è¯ç‰©å½±å“ (é™¤å¤–åŒ–å­¦ç‰©è´¨/è¯ç‰©å¼•èµ·çš„æ€§åŠŸèƒ½éšœç¢)ã€‚æˆ‘ä»¬å¿…é¡»è¦è®°ä½ï¼Œå¥³æ€§ç»å¸¸ç»å†ä¸æ­¢ä¸€ç§ç±»å‹çš„æ€§åŠŸèƒ½éšœç¢ã€‚å³ä½¿å¥³æ€§çš„æ€§åŠŸèƒ½ç—‡çŠ¶ä¸ç¬¦åˆDSM-5æ ‡å‡†ï¼Œå¥¹ä»ç„¶å¯ä»¥ä»æ€§åŠŸèƒ½è¯„ä¼°å’Œæ²»ç–—ä¸­è·ç›Šã€‚</p><p>å¿ƒç†å¹²é¢„åœ¨å¥³æ€§æ€§åŠŸèƒ½éšœç¢æ²»ç–—ä¸­çš„ä½œç”¨æ˜¯ä»€ä¹ˆï¼Ÿ</p><p>ä½œä¸ºå¥³æ€§æ€§åŠŸèƒ½éšœç¢æ²»ç–—çš„ä¸€éƒ¨åˆ†ï¼Œæˆ‘ä»¬å»ºè®®è¿›è¡Œå¿ƒç†å¹²é¢„ï¼ŒåŒ…æ‹¬æ€§æŠ€å·§è®­ç»ƒã€è¡Œä¸ºè®¤çŸ¥æ²»ç–—(åŒ…æ‹¬è¯ç‰©æ²»ç–—æˆ–éè¯ç‰©æ²»ç–—)ã€åŸºäºå¿ƒæ™ºè§‰çŸ¥çš„æ²»ç–—å’Œå¤«å¦»æ²»ç–—ã€‚åº”ç»¼åˆè€ƒè™‘å¦‡äº§ç§‘åŒ»ç”Ÿçš„ä¸“ä¸šæ°´å¹³å’Œæ‚£è€…çš„ä¸ªäººæ²»ç–—æ„æ„¿ï¼Œå‘å…·æœ‰æ²»ç–—å¥³æ€§æ€§åŠŸèƒ½éšœç¢æ–¹é¢çš„ä¸“ä¸šçŸ¥è¯†å¹¶æ¥å—è¿‡åŸ¹è®­çš„ç²¾ç¥å«ç”Ÿä¸“å®¶(å¦‚æ€§æ²»ç–—å¸ˆã€å¿ƒç†å­¦å®¶ã€ç²¾ç¥ç—…å­¦å®¶å’Œå©šå§»/æƒ…æ„Ÿå…³ç³»é¡¾é—®)å’¨è¯¢æˆ–æ¨ä»‹ã€‚</p><p>æ€§æŠ€èƒ½è®­ç»ƒï¼Œå¦‚æ‰‹æ·«æŒ‡å¯¼ï¼Œé•¿æœŸä»¥æ¥ä¸€ç›´æ˜¯æ²»ç–—æ€§é«˜æ½®éšœç¢çš„ä¸»è¦æ–¹æ³•(59)ã€‚ä¸€äº›æœ‰é«˜æ½®éšœç¢çš„æ‚£è€…ç¡®å®é€šè¿‡æ‰‹æ·«æˆ–å…¶ä»–æ€§åˆºæ¿€ä½“éªŒåˆ°äº†æ€§é«˜æ½®ï¼Œä½†ä»–ä»¬å¹¶ä¸è®¤ä¸ºè¿™äº›ä½“éªŒå°±æ˜¯é«˜æ½®ã€‚åœ¨å…¶ä»–æ¡ˆä¾‹å½“ä¸­ï¼Œå¥³æ€§ç¼ºä¹å…³äºé˜´è’‚åˆºæ¿€çš„çŸ¥è¯†æˆ–ç»éªŒï¼Œä»¥åŠè®¤ä¸ºé˜´è’‚åˆºæ¿€æ˜¯ä¸è¢«å…è®¸çš„æˆ–è€…å¯¹æ‰‹æ·«æ„Ÿåˆ°å†…ç–šå’Œç¾æ„§ï¼Œéƒ½æ˜¯å¼•å‘æ€§åŠŸèƒ½éšœç¢çš„åŸå›  (60)ã€‚é€šè¿‡åŠ å¼ºä¸æ€§ä¼´ä¾£è¿›è¡Œæ€§éœ€æ±‚å’Œæ€§åå¥½çš„æ²Ÿé€š,è¿›è¡Œæ„Ÿè§‰é›†ä¸­ç»ƒä¹ ï¼Œå’Œç³»ç»Ÿè„±æ•ç–—æ³•(61)ä»¥åŠåŠ å¼ºæ•™è‚²å’Œè¡Œä¸ºæŠ€æœ¯è®­ç»ƒï¼Œæ”¹å˜å¥³æ€§æ¶ˆææ€åº¦å’Œå‡è½»ç„¦è™‘æƒ…ç»ªï¼Œæ¥å¢åŠ å¥³æ€§èº«ä½“èˆ’é€‚åº¦å’Œæ€§æ¬²æœ›(60)ã€‚é­å—è¿‡æ€§ä¾µçŠ¯çš„å¥³æ€§æ€§é«˜æ½®éšœç¢æ‚£è€…å¯èƒ½ä¼šå—ç›Šäºåˆ›ä¼¤å¿ƒç†æ²»ç–— (62)ã€‚åŸºäºå°ç»„çš„æˆ–åŸºäºå¤«å¦»çš„è®¤çŸ¥è¡Œä¸ºç–—æ³•ä¸“æ³¨äºè¯†åˆ«å’Œæ”¹å˜åŠŸèƒ½å¤±è°ƒä¿¡å¿µï¼Œå¯èƒ½æœ‰åŠ©äºæ”¹å–„æ€§æ¬²ä½ä¸‹ (61ï¼Œ63-65)ã€‚å¿ƒæ™ºè§‰çŸ¥ç–—æ³•ï¼Œæ˜¯åªä¸“æ³¨äºä½“éªŒå½“ä¸‹ï¼Œä¸åŠ åˆ¤æ–­åœ°æ¥å—è‡ªå·±çš„æƒ³æ³•å’Œæ„Ÿå—ï¼Œå·²è¢«è¯æ˜æœ‰åŠ©äºæ”¹å–„å‡ ç§ä¸åŒç±»å‹çš„å¥³æ€§æ€§åŠŸèƒ½éšœç¢ï¼ŒåŒ…æ‹¬æ€§æ¬²/è§‰é†’éšœç¢å’Œè·å¾—æ€§é«˜æ½®ç¼ºä¹ç—‡(61,66)ã€‚</p><p><strong>ä¸“å®¶ç®€ä»‹</strong></p><div class=pgc-img><img alt="æŒ‡å—é€Ÿé€’ | 2019 ACOGå®è·µç®€æŠ¥ï¼šå¥³æ€§æ€§åŠŸèƒ½éšœç¢ï¼ˆNo.213ï¼‰ï¼ˆä¸Šï¼‰" onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/b19755408d9c492089dc0763d15a8226><p class=pgc-img-caption></p></div><p>å¾æ™–</p><p>å¾æ™–ï¼Œç”·ï¼Œ1973å¹´3æœˆå‡ºç”Ÿã€‚1997å¹´6æœˆæ¯•ä¸šäºå±±ä¸œåŒ»ç§‘å¤§å­¦ä¸´åºŠåŒ»å­¦ç³»ï¼Œè·å¾—å­¦å£«å­¦ä½ï¼Œ2010å¹´6æœˆæ¯•ä¸šäºå±±ä¸œå¤§å­¦åŒ»å­¦é™¢ï¼Œè·å¾—å¦‡äº§ç§‘ç¡•å£«å­¦ä½ã€‚è‡ª1997å¹´7æœˆè‡³ä»Šåœ¨åœ¨å±±ä¸œå¤§å­¦ç¬¬äºŒåŒ»é™¢å¦‡äº§ç§‘ä»äº‹ä¸´åºŠåŒ»ç–—å·¥ä½œã€‚2013å¹´9æœˆè˜ä¸ºå‰¯ä¸»ä»»åŒ»å¸ˆã€‚ä¸»è¦æ“…é•¿å¦‡ç§‘è‚¿ç˜¤ã€å¾®åˆ›é¢†åŸŸã€‚æ‰¿æ‹…å±±ä¸œçœç§‘æŠ€å…åŠå«è®¡å§”åŸºé‡‘é¡¹ç›®å„ä¸€é¡¹ï¼Œè¿„ä»Šåœ¨å›½å†…å¤–æ‚å¿—å‘è¡¨è®ºæ–‡7ç¯‡ï¼ŒSCIæ”¶å½•2ç¯‡, ä¸»ç¼–ä¸“ç€2éƒ¨ï¼Œå‚ç¼–ä¸“ç€7éƒ¨ã€‚</p><p>ä¸»è¦ç¤¾ä¼šå…¼èŒ</p><p>1.å±±ä¸œä¸­è¥¿åŒ»ç»“åˆå­¦ä¼šç”Ÿæ®–å†…åˆ†æ³Œä¸“ä¸šå§”å‘˜ä¼šå¸¸åŠ¡å§”å‘˜</p><p>2.å±±ä¸œçœå¾®é‡å…ƒç´ ç§‘å­¦ç ”ç©¶ä¼šå¦‡äº§ç§‘ä¸“ä¸šå§”å‘˜ä¼šç¬¬ä¸€å±Šå§”å‘˜</p><p>3.å±±ä¸œçœæŠ—ç™Œåä¼šå¦‡ç§‘è‚¿ç˜¤åˆ†ä¼šé¦–å±Šé’å¹´å§”å‘˜ä¼šå§”å‘˜</p><p>4.å±±ä¸œçœåŒ»å¸ˆåä¼šå¦‡ç§‘å¾®åˆ›åŒ»å¸ˆåˆ†ä¼šç¬¬ä¸€å±Šå§”å‘˜ä¼šå§”å‘˜</p><p>5. å±±ä¸œçœåŒ»å¸ˆåä¼šå¦‡äº§ç§‘åŒ»å¸ˆåˆ†ä¼šå­å®«å†…è†œå¼‚ä½ç—‡å’Œæ…¢æ€§ç›†è…”ç—›å§”å‘˜ä¼šç¬¬ä¸€å±Šå§”å‘˜</p><p>6. æµå—å¸‚å¥åº·æœåŠ¡ä¿ƒè¿›ä¼šå¸¸åŠ¡ç†äº‹</p><p>å‚è€ƒæ–‡çŒ®</p><p>1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): APA; 2013. (Level III)</p><p>2. Kingsberg SA. Taking a sexual history. Obstet Gynecol Clin North Am 2006;33:535â€“47. (Level III)</p><p>3. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008;112:970â€“8. (Level II-3)</p><p>4. Kinsey AC. Sexual behavior in the human female. Philadelphia (PA): Saunders; 1953. (Level III)</p><p>5. Masters WH, Johnson VE. Human sexual response. Boston (MA): Little, Brown and Company; 1966. (Level III)</p><p>6. Kaplan HS. Disorders of sexual desire and other new concepts and techniques in sex therapy. New York (NY): Simon and Schuster; 1979. (Level III)</p><p>7. Basson R. Sexuality and sexual disorders. Clin Update Womens Health Care 2014;XIII(2):1â€“108. (Level III)</p><p>8. Archer JS, Love-Geffen TE, Herbst-Damm KL, Swinney DA, Chang JR. Effect of estradiol versus estradiol and testosterone on brain-activation patterns in postmenopausal women. Menopause 2006;13:528â€“37. (Level III)</p><p>9. Davis SR, Guay AT, Shifren JL, Mazer NA. Endocrine aspects of female sexual dysfunction. J Sex Med 2004;1: 82â€“6. (Level III)</p><p>10. Kingsberg SA, Clayton AH, Pfaus JG. The female sexual response: current models, neurobiological underpinnings and agents currently approved or under investigation for the treatment of hypoactive sexual desire disorder. CNS Drugs 2015;29:915â€“33. (Level III)</p><p>11. Salonia A, Giraldi A, Chivers ML, Georgiadis JR, Levin R, Maravilla KR, et al. Physiology of womenâ€™s sexual function: basic knowledge and new findings. J Sex Med 2010;7:2637â€“60. (Level III)</p><p>12. Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Womenâ€™s Sexual Health and the North American Menopause Society. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Menopause 2014;21:1063â€“8. (Level III)</p><p>13. Burger HG, Papalia MA. A clinical update on female androgen insufficiencyâ€”testosterone testing and treatment in women presenting with low sexual desire. Sex Health 2006;3:73â€“8. (Level III)</p><p>14. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90:3847â€“53. (Level II-3)</p><p>15. Kingsberg SA. The impact of aging on sexual function in women and their partners. Arch Sex Behav 2002;31:431â€“ 7. (Level III)</p><p>16. Santoro N, Torrens J, Crawford S, Allsworth JE, Finkelstein JS, Gold EB, et al. Correlates of circulating androgens in mid-life women: the study of womenâ€™s health across the nation. J Clin Endocrinol Metab 2005; 90:4836â€“45. (Level II-3)</p><p>17. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005;294:91â€“6. (Level II-3)</p><p>18. Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2014;99:3489â€“510. (Systematic Review)</p><p>19. Abdool Z, Thakar R, Sultan AH. Postpartum female sexual function. Eur J Obstet Gynecol Reprod Biol 2009;145: 133â€“7. (Level III)</p><p>20. Cabral PU, Canario AC, Spyrides MH, Uchoa SA, Eleuterio J Jr, Goncalves AK. Determinants of sexual dysfunction among middle-aged women. Int J Gynaecol Obstet 2013;120:271â€“4. (Level II-3)</p><p>21. Dean J, Rubio-Aurioles E, McCabe M, Eardley I, Speakman M, Buvat J, et al. Integrating partners into erectile dysfunction treatment: improving the sexual experience for the couple. Int J Clin Pract 2008;62:127â€“33. (Level III)</p><p>22. Galazka I, Drosdzol-Cop A, Naworska B, Czajkowska M, Skrzypulec-Plinta V. Changes in the sexual function during pregnancy. J Sex Med 2015;12:445â€“54. (Level II-2)</p><p>23. Kalmbach DA, Arnedt JT, Pillai V, Ciesla JA. The impact of sleep on female sexual response and behavior: a pilot study. J Sex Med 2015;12:1221â€“32. (Level II-2)</p><p>24. McCabe MP, Sharlip ID, Lewis R, Atalla E, Balon R, Fisher AD, et al. Risk factors for sexual dysfunction among women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. J Sex Med 2016;13:153â€“67. (Level III)</p><p>25. Ter Kuile MM, Vigeveno D, Laan E. Preliminary evidence that acute and chronic daily psychological stress affect sexual arousal in sexually functional women. Behav Res Ther 2007;45:2078â€“89. (Level I) 26. Wiederman MW. Womenâ€™s body image selfconsciousness during physical intimacy with a partner. J Sex Res 2000;37:60â€“8. (Level II-3)</p><p>27. Basson R, Leiblum S, Brotto L, Derogatis L, Fourcroy J, Fugl-Meyer K, et al. Revised definitions of womenâ€™s sexual dysfunction. J Sex Med 2004;1:40â€“8. (Level III)</p><p>28. Rosen RC, Shifren JL, Monz BU, Odom DM, Russo PA, Johannes CB. Correlates of sexually related personal distress in women with low sexual desire. J Sex Med 2009;6: 1549â€“60. (Level II-2)</p><p>29. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009;29:259â€“66. (Meta-analysis)</p><p>30. Berg RC, Underland V, Odgaard-Jensen J, Fretheim A, Vist GE. Effects of female genital cutting on physical health outcomes: a systematic review and meta-analysis. BMJ Open 2014;4:e006316. (Systematic Review and Meta-analysis)</p><p>31. Basson R. Female sexual response: the role of drugs in the management of sexual dysfunction [published erratum appears in Obstet Gynecol 2001;98:522]. Obstet Gynecol 2001;98:350â€“3. (Level III) 32. Steege JF, Zolnoun DA. Evaluation and treatment of dyspareunia. Obstet Gynecol 2009;113:1124â€“36. (Level III)</p><p>33. Macleod M, Goyder K, Howarth L, Bahl R, Strachan B, Murphy DJ. Morbidity experienced by women before and after operative vaginal delivery: prospective cohort study nested within a two-centre randomised controlled trial of restrictive versus routine use of episiotomy. BJOG 2013; 120:1020â€“6. (Level I)</p><p>34. McDonald E, Woolhouse H, Brown SJ. Consultation about sexual health issues in the year after childbirth: a cohort study. Birth 2015;42:354â€“61. (Level II-2)</p><p>35. McDonald EA, Gartland D, Small R, Brown SJ. Dyspareunia and childbirth: a prospective cohort study. BJOG 2015;122:672â€“9. (Level II-2)</p><p>36. Signorello LB, Harlow BL, Chekos AK, Repke JT. Postpartum sexual functioning and its relationship to perineal trauma: a retrospective cohort study of primiparous women. Am J Obstet Gynecol 2001;184:881â€“8; discussion 888â€“90. (Level II-2)</p><p>37. DeJudicibus MA, McCabe MP. Psychological factors and the sexuality of pregnant and postpartum women. J Sex Res 2002;39:94â€“103. (Level II-3)</p><p>38. Screening for perinatal depression. ACOG Committee Opinion No. 757. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;132:e208â€“12. (Level III)</p><p>39. Intimate partner violence. Committee Opinion No. 518. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;119:412â€“7. (Level III)</p><p>40. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133â€“42. (Level II-3)</p><p>41. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey. Climacteric 2012;15:36â€“44. (Level II-3)</p><p>42. Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc 2017;92:1842â€“9. (Level III)</p><p>43. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888-902; quiz 903â€“4. (Level III)</p><p>44. Sexual health. Committee Opinion No. 706. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130:e42â€“7. (Level III)</p><p>45. Simon JA, Lukas VA. Distressing sexual function at midlife: unmet needs, practical diagnoses, and available treatments. Obstet Gynecol 2017;130:889â€“905. (Level III)</p><p>46. Kingsberg S. Just ask! Talking to patients about sexual function. Sex Reprod Menopause 2004;2:199â€“203. (Level III)</p><p>47. Flynn KE, Lindau ST, Lin L, Reese JB, Jeffery DD, Carter J, et al. Development and validation of a singleitem screener for self-reporting sexual problems in U.S. adults. J Gen Intern Med 2015;30:1468â€“75. (Level II-2)</p><p>48. Parish SJ, Hahn SR. Hypoactive sexual desire disorder: a review of epidemiology, biopsychology, diagnosis, and treatment. Sex Med Rev 2016;4:103â€“20. (Level III)</p><p>49. Althof SE, Rosen RC, Perelman MA, Rubio-Aurioles E. Standard operating procedures for taking a sexual history. J Sex Med 2013;10:26â€“35. (Level III)</p><p>50. Hatzichristou D, Rosen RC, Derogatis LR, Low WY, Meuleman EJ, Sadovsky R, et al. Recommendations for the clinical evaluation of men and women with sexual dysfunction. J Sex Med 2010;7:337â€“48. (Level III)</p><p>51. Nusbaum MR, Hamilton CD. The proactive sexual health history. Am Fam Physician 2002;66:1705â€“12. (Level III)</p><p>52. Reproductive and sexual coercion. Committee Opinion No. 554. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;121:411â€“5. (Level III)</p><p>53. Latif EZ, Diamond MP. Arriving at the diagnosis of female sexual dysfunction. Fertil Steril 2013;100:898â€“ 904. (Level III)</p><p>54. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191â€“208. (Level 111)</p><p>55. Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J. The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther 2002;28:317â€“30. (Level III)</p><p>56. Lindau ST, Abramsohn EM, Baron SR, Florendo J, Haefner HK, Jhingran A, et al. Physical examination of the female cancer patient with sexual concerns: What oncologists and patients should expect from consultation with a specialist. CA Cancer J Clin 2016;66:241â€“63. (Level III)</p><p>57. Witzeman K, Nguyen RH, Eanes A, As-Sanie S, Zolnoun D. Mucosal versus muscle pain sensitivity in provoked vestibulodynia. J Pain Res 2015;8:549â€“55. (Level II-2)</p><p>58. Vieira-Baptista P, Lima-Silva J, Beires J, Donders G. Women without vulvodynia can have a positive â€œQ-tip testâ€: a cross sectional study. J Psychosom Obstet Gynaecol 2017;38:256â€“9. (Level II-3)</p><p>59. Heiman JR, Meston CM. Empirically validated treatment for sexual dysfunction. Annu Rev Sex Res 1997;8:148â€“ 94. (Level III)</p><p>60. Meston CM, Levin RJ, Sipski ML, Hull EM, Heiman JR. Womenâ€™s orgasm. Annu Rev Sex Res 2004;15:173â€“257. (Level III)</p><p>61. Brotto L, Atallah S, Johnson-Agbakwu C, Rosenbaum T, Abdo C, Byers ES, et al. Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med 2016;13:538â€“71. (Systematic Review)</p><p>62. Zoldbrod AP. Sexual issues in treating trauma survivors. Curr Sex Health Rep 2015;7:3â€“11. (Level III) 63. Fruhauf S, Gerger H, Schmidt HM, Munder T, Barth J. Efficacy of psychological interventions for sexual dysfunction: a systematic review and meta-analysis. Arch Sex Behav 2013;42:915â€“33. (Systematic Review)</p><p>64. Faubion SS, Rullo JE. Sexual dysfunction in women: a practical approach [published erratum appears in Am Fam Physician 2016;94:189]. Am Fam Physician 2015; 92:281â€“8. (Level III)</p><p>65. Gunzler C, Berner MM. Efficacy of psychosocial interventions in men and women with sexual dysfunctionsâ€” a systematic review of controlled clinical trials: part 2â€” the efficacy of psychosocial interventions for female sexual dysfunction. J Sex Med 2012;9:3108â€“25. (Systematic Review)</p><p>66. Brotto LA, Basson R, Luria M. A mindfulness-based group psychoeducational intervention targeting sexual arousal disorder in women. J Sex Med 2008;5:1646â€“59. (Level II-3)</p><p>67. Lindau ST, Dude A, Gavrilova N, Hoffmann JN, Schumm LP, McClintock MK. Prevalence and correlates of vaginal estrogenization in postmenopausal women in the United States. Menopause 2017;24:536â€“45. (Level II-2)</p><p>68. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews 2016, Issue 8. Art. No.: CD001500. DOI: 10.1002/14651858.CD001500. pub3. (Systematic Review)</p><p>69. Mitchell CM, Reed SD, Diem S, Larson JC, Newton KM, Ensrud KE, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. JAMA Intern Med 2018;178:681â€“90. (Level I)</p><p>70. Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric 2015;18:121â€“34. (Level III)</p><p>71. Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Society of Gynecologic Surgeons Systematic Review Group. Obstet Gynecol 2014;124:1147â€“56. (Systematic Review)</p><p>72. Management of menopausal symptoms. Practice Bulletin No. 141. American College of Obstetricians and Gynecologists [published erratum appears in Obstet Gynecol 2016;127:166]. Obstet Gynecol 2014;123:202â€“16. (Level III)</p><p>73. The 2017 hormone therapy position statement of The North American Menopause Society. The</p><p>NAMS 2017Hormone Therapy Position Statement Advisory Panel. Menopause 2017;24:728â€“53. (Level III)</p><p>74. Cui Y, Zong H, Yan H, Li N, Zhang Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med 2014;11: 487â€“97. (Systematic Review)</p><p>75. Portman D, Palacios S, Nappi RE, Mueck AO. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas 2014;78:91â€“ 8. (Level I)</p><p>76. Constantine GD, Goldstein SR, Archer DF. Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. Menopause 2015;22:36â€“43. (Level II-1)</p><p>77. The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Committee Opinion No. 659. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016;127:e93â€“6. (Level III)</p><p>78. Management of gynecologic issues in women with breast cancer. Practice Bulletin No. 126. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012; 119:666â€“82. (Level III)</p><p>79. Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 2002;99:556â€“62. (Level I)</p><p>80. Achilli C, Pundir J, Ramanathan P, Sabatini L, Hamoda H, Panay N. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil Steril 2017;107:475â€“82.e15. (Systematic Review and Meta-analysis)</p><p>81. Shifren JL, Gass ML. The North American Menopause Society recommendations for clinical care of midlife women. NAMS Recommendations for Clinical Care of Midlife Women Working Group. Menopause 2014;21: 1038â€“62. (Level III)</p><p>82. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005;165: 1582â€“9. (Level I)</p><p>83. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005;105:944â€“52. (Level I)</p><p>84. Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot C, Rees M, et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial [published erratum appears in Menopause 2006;13:850]. Menopause 2006;13:387â€“96. (Level I)</p><p>85. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study [published erratum appears in Menopause 2007;14:157]. Menopause 2006;13:770â€“9. (Level I)</p><p>86. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005; 90:5226â€“33. (Level I)</p><p>87. Davis S, Papalia MA, Norman RJ, Oâ€™Neill S, Redelman M, Williamson M, et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med 2008;148:569â€“77. (Level I)</p><p>88. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 2003;10:390â€“8. (Level II-3)</p><p>89. Hakim C, Padmanabhan V, Vyas AK. Gestational hyperandrogenism in developmental programming. Endocrinology 2017;158:199â€“212. (Level III)</p><p>90. Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, et al. Testosterone for low libido in postmenopausal women not taking estrogen. APHRODITE Study Team. N Engl J Med 2008;359:2005â€“17. (Level I)</p><p>91. Panay N, Al-Azzawi F, Bouchard C, Davis SR, Eden J, Lodhi I, et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 2010;13:121â€“31. (Level I)</p><p>92. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiolâ€™s effects on postmenopausal bone density and sexuality. Maturitas 2008;61:17â€“26. (Level I)</p><p>93. Nachtigall L, Casson P, Lucas J, Schofield V, Melson C, Simon JA. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol 2011;27:39â€“48. (Level I)</p><p>94. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003;79:1341â€“ 52. (Level I)</p><p>95. Sherwin BB. Use of combined estrogen-androgen preparations in the postmenopause: evidence from clinical studies. Int J Fertil Womens Med 1998;43:98â€“103. (Level III)</p><p>96. Davis SR, Braunstein GD. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2012;9: 1134â€“48. (Level III)</p><p>97. Urman B, Pride SM, Yuen BH. Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy. Obstet Gynecol 1991;77:595â€“8. (Level III) 98. Ness RB, Albano JD, McTiernan A, Cauley JA. Influence of estrogen plus testosterone supplementation on breast cancer. Arch Intern Med 2009;169:41â€“6. (Level II-2)</p><p>99. Elraiyah T, Sonbol MB, Wang Z, Khairalseed T, Asi N, Undavalli C, et al. Clinical review: the benefits and harms of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.</p><p>100. Panjari M, Bell RJ, Jane F, Wolfe R, Adams J, Morrow C, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med 2009;6:2579â€“90. (Level I)</p><p>101. Scheffers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V. Dehydroepiandrosterone for women in the perior postmenopausal phase. Cochrane Database of Systematic Reviews 2015, Issue 1. Art. No.: CD011066. DOI: 10.1002/14651858.CD011066.pub2. (Systematic Review and Meta-analysis) 102. Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ET. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med 2016;176:453â€“62. (Systematic Review and Metaanalysis)</p><p>103. Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M Jr, Sand M. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause 2014;21: 633â€“40. (Level I)</p><p>104. ADDY (flibanserin) tablets 100 mg. Raleigh (NC): Sprout Pharmaceuticals, Inc; 2018. Available at: https:// addyi.com/assets/pdf/Addyi_full_prescribing_info.pdf. Retrieved February 26, 2019. (Level III)</p><p>105. Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial. BJOG 2003;110:1014â€“24. (Level I)</p><p>106. Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002;11: 367â€“77. (Level I)</p><p>107. Berman JR, Berman LA, Toler SM, Gill J, Haughie S. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. Sildenafil Study Group. J Urol 2003; 170:2333â€“8. (Level I)</p><p>108. Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebocontrolled study. BJOG 2001;108:623â€“8. (Level II-3)</p><p>109. Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA 2008;300:395â€“404. (Level I)</p><p>110. Taylor MJ, Rudkin L, Bullemorâ€Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD003382. DOI: 10.1002/14651858. CD003382.pub3.(Systematic Review and Meta-analysis)</p><p>111. Safarinejad MR. Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study. J Psychopharmacol 2011;25:370â€“8. (Level I)</p><p>112. Wilson SK, Delk JR 2nd, Billups KL. Treating symptoms of female sexual arousal disorder with the Eros-Clitoral Therapy Device. J Gend Specif Med 2001;4:54â€“8. (Level III)</p><p>113. Billups KL. The role of mechanical devices in treating female sexual dysfunction and enhancing the female sexual response. World J Urol 2002;20:137â€“41. (Level III)</p><p>114. Guess MK, Connell KA, Chudnoff S, Adekoya O, Richmond C, Nixon KE, et al. The effects of a genital vibratory stimulation device on sexual function and genital sensation. Female Pelvic Med Reconstr Surg 2017;23: 256â€“62. (Level II-2)</p><p>115. Persistent vulvar pain. Committee Opinion No. 673. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016;128:e78â€“84. (Level III)</p><p>116. Paquet M, Rosen NO, Steben M, Mayrand MH, SanterreBaillargeon M, Bergeron S. Daily anxiety and depressive symptoms in couples coping with vulvodynia: associations with womenâ€™s pain, womenâ€™s sexual function, and both partnersâ€™ sexual distress. J Pain 2018;19:552â€“61. (Level II-3)</p><p>117. Melles RJ, Dewitte MD, Ter Kuile MM, Peters MM, de Jong PJ. Attentional bias for pain and sex, and automatic appraisals of sexual penetration: differential patterns in dyspareunia vs vaginismus? J Sex Med 2016;13:1255â€“ 62. (Level II-1)</p><p>118. Leo RJ, Dewani S. A systematic review of the utility of antidepressant pharmacotherapy in the treatment of vulvodynia pain. J Sex Med 2013;10:2497â€“505. (Systematic Review)</p><p>119. Melnik T, Hawton K, McGuire H. Interventions for vaginismus. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD001760. DOI: 10.1002/14651858. CD001760.pub2. (Systematic Review)</p><p>120. Reissing ED, Armstrong HL, Allen C. Pelvic floor physical therapy for lifelong vaginismus: a retrospective chart review and interview study. J Sex Marital Ther 2013;39: 306â€“20. (Level III)</p><p>121. Ter Kuile MM, Melles R, de Groot HE, TuijnmanRaasveld CC, van Lankveld JJDM. Therapist-aided exposure for women with lifelong vaginismus: a randomized waiting-list control trial of efficacy. J Consult Clin Psychol 2013;81:1127â€“36. (Level I)</p><p>122. Haefner HK, Collins ME, Davis GD, Edwards L, Foster DC, Hartmann ED, et al. The vulvodynia guideline. J Low Genit Tract Dis 2005;9:40â€“51. (Level III)</p><p>123. Polpeta NC, Giraldo PC, Teatin Juliato CR, Gomes Do Amaral RL, Moreno Linhares I, Romero Leal Passos M. Clinical and therapeutic aspects of vulvodynia: the importance of physical therapy. Minerva Ginecol 2012;64:437â€“ 45. (Level III)</p><p>124. Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia</p><p>125. Crisp CC, Vaccaro CM, Estanol MV, Oakley SH, Kleeman SD, Fellner AN, et al. Intra-vaginal diazepam for high-tone pelvic floor dysfunction: a randomized placebo-controlled trial. Int Urogynecol J 2013;24: 1915â€“23. (Level I)</p><p>126. Leo RJ. A systematic review of the utility of anticonvulsant pharmacotherapy in the treatment of vulvodynia pain. J Sex Med 2013;10:2000â€“8. (Systematic Review)</p><p>127. Foster DC, Kotok MB, Huang LS, Watts A, Oakes D, Howard FM, et al. Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. Obstet Gynecol 2010;116:583â€“93. (Level I)</p><p>128. Reed SD, Mitchell CM, Joffe H, Cohen L, Shifren JL, Newton KM, et al. Sexual function in women on estradiol or venlafaxine for hot flushes: a randomized controlled trial. Obstet Gynecol 2014;124:233â€“41. (Level I)</p><p>129. Nesbitt-Hawes EM, Won H, Jarvis SK, Lyons SD, Vancaillie TG, Abbott JA. Improvement in pelvic pain with botulinum toxin type Aâ€”single vs. repeat injections. Toxicon 2013;63:83â€“7. (Level I)</p><p>130. Lara LA, Useche B, Ferriani RA, Reis RM, de Sa MF, de Freitas MM, et al. The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response. J Sex Med 2009;6:30â€“9. (Level III)</p><p>131. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87â€“94. (Level III)</p><p>132. Santoro N, Worsley R, Miller KK, Parish SJ, Davis SR. Role of estrogens and estrogen-like compounds in female sexual function and dysfunction. J Sex Med 2016;13:305â€“ 16. (Level III)</p><p>133. Chen J, Geng L, Song X, Li H, Giordan N, Liao Q. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. J Sex Med 2013;10:1575â€“84. (Level I)</p><p>134. Juraskova I, Jarvis S, Mok K, Peate M, Meiser B, Cheah BC, et al. The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer. J Sex Med 2013;10:2549â€“58. (Level II-2)</p><p>135. Sokol ER, Karram MM. An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy. Menopause 2016;23:1102â€“7. (Level III)</p><p>136. Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric 2014;17:363â€“9. (Level III)</p><p>137. American College of Obstetricians and Gynecologists. Fractional laser treatment of vulvovaginal atrophy and U.S. Food and Drug Administration clearance. Position Statement. Washington, DC: ACOG; 2016. Available at: https://www.acog.org/Clinical-Guidance-and-Publications/ Position-Statements/Fractional-Laser-Treatment-of-VulvovaginalAtrophy-and-US-Food-and-Drug-Administration-Clearance. Retrieved February 13, 2019. (Level III) e</p></div></div><div class="post-meta meta-tags"><ul class=clearfix><li><a>'é€Ÿé€’','2019','ACOG'</a></li></ul></div></article></div></div><div id=secondary><section class=widget><form id=search action=//www.google.com/search method=get accept-charset=utf-8 target=_blank _lpchecked=1><input type=text name=q maxlength=20 placeholder=æœç´¢>
<input type=hidden name=sitesearch value=geekbank.cf>
<button type=submit>ğŸ”</button></form></section><section class=widget><h3 class=widget-title>æœ€æ–°æ–‡ç«  âš¡</h3><ul class=widget-list></ul></section><section class=widget><h3 class=widget-title>å…¶ä»–</h3><ul class=widget-list><li><a href=TOS.html>ä½¿ç”¨æ¢æ¬¾</a></li><li><a href=CommentPolicy.html>ç•™è¨€æ”¿ç­–</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>DMCA</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>è¯çµ¡æˆ‘å€‘</a></li></ul></section></div></div></div></div><footer id=footer><div class=container>&copy; 2020 <a href>æå®¢å¿«è¨Š</a></div></footer><script type=text/javascript>window.MathJax={tex2jax:{inlineMath:[['$','$']],processEscapes:true}};</script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML" async></script><a id=rocket href=#top></a><script type=text/javascript src=https://kknews.cf/js/totop.js async></script><script type=application/javascript>var doNotTrack=false;if(!doNotTrack){window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;ga('create','UA-146415161-2','auto');ga('send','pageview');}</script><script async src=https://www.google-analytics.com/analytics.js></script><script type=text/javascript src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-5e508ed9e4e698bb"></script></body></html>